ArticleScientific reports2025
Evolving patient preferences from surgery to thermal ablation in solitary thyroid nodule treatment.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of transoral endoscopic thyroidectomy vestibular approach of papillary thyroid carcinoma: a network meta-analysis.Frontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A changing landscape of patients' preferences for treatment of solitary and benign thyroid nodules (SBTN) form conventional surgery to other minimally invasive treatments (MITs) has been witnessed. The aim of this study was to evaluate indications, patients' preferences and outcomes of conventional surgery vs. transoral endoscopic thyroid surgery by vestibular approach (TOETVA) vs. laser ablation (LA) treatments for SBTN. This prospective cohort study included patients with SBTN causing compression symptoms treated at our institution throughout 2020-2023. Primary endpoint was patients' preferences for treatment. Secondary endpoints were: success rate, overall morbidity, need for second line treatment, and satisfaction rate. Some 204 patients (F: M = 161:43) with SBTN were offered conventional surgery (thyroid lobectomy) vs. TOETVA vs. LA. Patients' preferences were: 23 (11.3%) for conventional surgery vs. 17 (8.3%) for TOETVA vs. 164 (80.4%) for LA (p < 0.01). Overall morbidity was 2/23 (8.7%) for conventional surgery vs. 2/17 (11.8%) for TOETVA vs. 3/164 (1.8%) for LA (p < 0.01). Volume reduction ratio (VRR) for LA was 63% (range: 32 - 98%) at 6 months following treatment. Spongiform nodules vs. predominantly solid tumors vs. solid tumors had VRR of 83% vs. 67% vs. 51%, respectively (p < 0.01). Second line treatment was needed for 3/101 (3.0%) patients following LA within a 3-year follow-up. Satisfaction rate was higher for LA and TOETVA vs. conventional surgery (p < 0.01). Currently most patients prefer MITs for SBTN. TOETVA is chosen by minority of patients with a strong motivation to avoid scar whereas thermal ablation is the preferred MIT nowadays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.